To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

Safety and Tolerability Study of Sublingual Lobeline

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00100074

Enrollment

Registered

2004-12-23

Start date

2004-09-30

Completion date

2005-04-30

Last updated

2017-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphetamine-Related Disorders

Brief summary

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Detailed description

The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.

Interventions

DRUGLobeline

Study design

Primary purpose

DIAGNOSTIC

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy individuals with a body mass index between 18 and 30. * Willing and able to give written consent. * Must have a negative drug test * Females must have a negative pregnancy test prior to study drug administration * Must have no medical contraindications as determined by routine testing

Exclusion criteria

* Please contact the site for more information

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026